Psoriasis and diabetes share inflammatory roots. People with psoriasis have about 1.5 to 2 times the risk of type 2 diabetes, with the highest risk in severe disease. The same TNF-alpha, IL-17, and IL-23 cytokines that produce psoriatic plaques also promote insulin resistance. Modern biologic therapies are largely glucose-neutral and can modestly improve metabolic markers. Cardiovascular risk is elevated and amplified when diabetes coexists.
How Psoriasis and Diabetes Overlap
- Shared cytokines — TNF-alpha, IL-17A, IL-23, IL-6
- Chronic inflammation promotes insulin resistance and beta-cell stress
- Higher rates of obesity and metabolic syndrome in psoriasis populations
- Both conditions independently raise cardiovascular risk
- Psoriatic arthritis adds joint inflammation and reduced activity
Risk by Psoriasis Severity
| Psoriasis Severity | Approximate Type 2 Diabetes Risk |
|---|---|
| Mild (less than 3 percent body surface area) | ~1.2 times general population |
| Moderate (3 to 10 percent body surface area) | ~1.5 times general population |
| Severe (more than 10 percent body surface area or PASI greater than 12) | ~2 times general population |
| Psoriatic arthritis | ~2 times general population |
Skin Signs to Watch For
- Well-demarcated, scaly plaques on elbows, knees, scalp, and lower back
- Nail pitting, ridging, or onycholysis (nail lifting)
- Pustular flares — sometimes triggered by infection or rapid steroid withdrawal
- Erythrodermic psoriasis — widespread redness; medical emergency
- Inverse psoriasis in skin folds (can be confused with intertrigo, common in diabetes)
- Acanthosis nigricans (insulin resistance marker) sometimes overlaps
Psoriasis Therapies and Glucose
- Topical corticosteroids — minimal systemic glucose effect at typical use
- Topical vitamin D analogs (calcipotriol) — no glucose effect
- Topical calcineurin inhibitors — no glucose effect
- Phototherapy (narrowband UVB) — no direct glucose effect
- Methotrexate — insulin-sensitizing tendency; monitor liver and kidney
- Cyclosporine — can raise blood pressure and slightly elevate glucose
- Apremilast (PDE4 inhibitor) — generally glucose-neutral; weight loss often seen
- TNF inhibitors (adalimumab, etanercept, infliximab, certolizumab) — glucose-neutral to favorable
- IL-17 inhibitors (secukinumab, ixekizumab, brodalumab) — glucose-neutral
- IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) — glucose-neutral
- IL-12/23 inhibitor (ustekinumab) — glucose-neutral
- JAK inhibitors (deucravacitinib, upadacitinib) — variable lipid effects; monitor
Cardiovascular Risk in Psoriasis + Diabetes
- Psoriasis alone raises risk of heart attack and stroke modestly
- Combined with diabetes, cardiovascular risk is substantially higher
- Lipid profile and blood pressure should be checked annually at minimum
- Statin therapy is often initiated earlier
- SGLT2 inhibitors or GLP-1 receptor agonists are preferred in many patients with type 2 + cardiovascular risk
- Smoking cessation reduces both psoriasis severity and diabetic complications
Psoriatic Arthritis Considerations
- 30 to 40 percent of people with psoriasis develop psoriatic arthritis
- Joint care overlaps with our coverage of rheumatoid arthritis and diabetes
- Methotrexate, TNF inhibitors, IL-17, and IL-23 inhibitors all used
- Glucocorticoid use should be minimized given diabetogenic effects
- Frozen shoulder and tendinopathy risks elevated in diabetes
Lifestyle Levers That Help Both Conditions
- Weight loss — even 5 to 10 percent reduction improves both
- Mediterranean-style diet rich in olive oil, fish, vegetables, and whole grains
- Alcohol moderation — alcohol worsens psoriasis severity and raises diabetes risk
- Smoking cessation
- Skin care routine — gentle cleansing, frequent moisturizing
- Stress management — flares often follow stress
- Sleep — both conditions worsen with poor sleep
When to Talk to Your Doctor
- Rapidly worsening or widespread plaques
- New joint pain or morning stiffness (possible psoriatic arthritis)
- Blood-pressure or lipid levels rising on cyclosporine
- New diabetes diagnosis or A1C creeping up
- Considering systemic therapy or biologics — coordinate with both dermatology and diabetes care
- Pregnancy planning
Related Reading
See our overview of complications and related conditions and our guides on diet and nutrition and treatment. Other autoimmune overlaps include multiple sclerosis and inflammatory bowel disease.
The Bottom Line
Psoriasis raises type 2 diabetes risk by about 1.5 to 2 times, with severe disease carrying the highest risk. Shared inflammation through TNF-alpha, IL-17, and IL-23 drives both conditions, and modern biologic therapies — TNF inhibitors, IL-17 inhibitors, and IL-23 inhibitors — are largely glucose-neutral and may modestly help metabolic markers by lowering inflammation. Cardiovascular risk is elevated and additive, so lipid, blood-pressure, and lifestyle interventions are central. Weight loss benefits both conditions, often improving response to biologics and insulin sensitivity together.
